Q4Bio

Q4Bio — Execution

Supports United Kingdom quantum biology research linking physics tools to biological discovery challenges.

Q4Bio (Quantum for Biology) is a $50 million Wellcome Leap program that funds multidisciplinary teams applying quantum computing to biological and health science problems. The program targets quantum computers expected to emerge over a 3–5 year horizon and requires performer teams to span three distinct expertise domains: health science, quantum software, and quantum hardware. Program Director Dr. Shihan Sajeed (quantum information science, University of Waterloo background) leads the initiative. The $50 million total is structured as up to $40 million in research funding plus up to $10 million in challenge prizes — $2 million per team for a successful quantum demonstration, plus a $5 million grand prize for the team achieving the highest specified quantum resource targets.

Performer teams were selected around 2023 for a 3–5 year execution window; Q4Bio is currently in active execution with no open solicitation. The program's challenge prize structure is unusual within Wellcome Leap's portfolio, supplementing the standard performer contract model with competition-style incentives tied to specific quantum milestone demonstrations. Eligible organizations for the original solicitation followed Wellcome Leap's global model — no country restrictions — with a hard requirement that teams be multiorganizational and multidisciplinary, combining health, quantum software, and quantum hardware expertise on a single team.

Organizations at the intersection of quantum computing and life sciences should monitor Wellcome Leap for any future Q4Bio solicitation cycles. The 3–5 year execution window beginning approximately 2023 suggests a possible re-solicitation or follow-on program in the 2027–2028 timeframe if the current cohort delivers its quantum demonstration milestones. The program is a rare example of a health-focused funder making substantial, sustained investment in quantum-biological applications at scale.